Abstract
Trifluridine/tipiracil is an oral combination therapy approved for patients with metastatic colorectal cancer (mCRC) refractory to, or not candidates for, available therapies based on the RECOURSE trial. It recently showed good and poor prognosis subgroups according to their tumour burden and presence of indolent disease, which improved when liver metastases were absent. We assessed the early clinical experience with trifluridine/tipiracil in Spain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
